CHChenyao Huang

Chenyao Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chenyao Huang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Qian Yang

    School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

    1 shared publication
  • Rui Shao

    State Key Laboratory of Chinese Medicine Modernization, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

    1 shared publication
  • Shiqi Wang

    State Key Laboratory of Chinese Medicine Modernization, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

    1 shared publication
  • Xin Zhao

    Ministry of Education Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae Tianjin University of Traditional Chinese Medicine Tianjin China

    1 shared publication
  • Yu Wang

    School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

    1 shared publication

Latest Publications

  • Medicinal and Edible Plants for the Management of Inflammatory Bowel Disease: Synergistic Modulation of the Microbiota–Metabolite–Immune Axis

    by Qian Yang, Shiqi Wang, Chenyao Huang, Rui Shao, Yu Wang, Xin Zhao

    Inflammatory bowel disease (IBD) is a chronic condition driven by the intertwined interplay of gut dysbiosis, immune perturbation, and metabolic imbalance. Current single-target therapies often fail to durably restore homeostasis in this complex ecosystem, and have thereby increased interest in diet-based holistic interventions. Plants traditionally used as both food and medicine, such as Crataegus pinnatifida, Ganoderma lucidum, and Codonopsis pilosula, are natural products that possess both nutritional and therapeutic attributes. The use of such plants is commonly referred to as medicinal food homology (MFH) in East Asian literature. Their multi-component nature offers the potential to modulate intestinal homeostasis through multi-target synergy. This review systematically discusses how MFH regulates the “microbiota–metabolite–immune” axis via key bioactive constituents like polysaccharides, curcumin, and geniposide. Specifically, these constituents differentially influence short-chain fatty acid (SCFA) production, oxidative stress, and bile-acid signaling to thereby enable integrated regulation of the gut micro-ecosystem and host immune function. In parallel, we critically address the translational challenges of extrapolating animal-model findings to clinical applications, and propose a precision-intervention framework that integrates chemical standardization, multi-omics, artificial intelligence, and advanced ex vivo validation models to both overcome MFH’s intrinsic complexity and facilitate evidence-based, personalized IBD management.